| Not Yet Recruiting | Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy NCT07426484 | Dana-Farber Cancer Institute | Phase 4 |
| Recruiting | TIL Therapy in cSCC and MCC NCT07288073 | Karam Khaddour, MD, MS | Phase 2 |
| Recruiting | Ex Vivo Cutaneous SCC NCT07402616 | Rigshospitalet, Denmark | N/A |
| Withdrawn | Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients NCT04329221 | Massachusetts General Hospital | Phase 2 |
| Withdrawn | Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients NCT04642287 | Massachusetts General Hospital | Phase 2 |
| Recruiting | Towards Cure Via Only Ultra-short ICB in CSCC NCT06823479 | The Netherlands Cancer Institute | Phase 2 |
| Withdrawn | Window of Opportunity Study of Topical Tranexamic Acid for Cutaneous Squamous Cell Carcinoma NCT06644079 | University of Florida | Phase 2 |
| Recruiting | ctDNA in Cutaneous Squamous Cell Carcinoma NCT06875609 | Massachusetts Eye and Ear Infirmary | — |
| Recruiting | Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma NCT06567314 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participa NCT06384820 | Regeneron Pharmaceuticals | Phase 2 |
| Recruiting | Thermotherapy in Addition to SOC Palliative Radiotherapy NCT06659146 | King's College London | N/A |
| Recruiting | Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis) NCT06577311 | The Center for Clinical and Cosmetic Research | Phase 2 |
| Recruiting | Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma NCT06288191 | Melanoma Institute Australia | Phase 2 |
| Active Not Recruiting | Exercise to Boost Response to Checkpoint Blockade Immunotherapy NCT06008977 | AdventHealth Translational Research Institute | N/A |
| Recruiting | B-catenin in Cutaneous Squamous Cell Carcinoma and Its Mimickers NCT06536946 | Sohag University | — |
| Recruiting | Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors NCT06171750 | Ankyra Therapeutics, Inc | Phase 1 |
| Unknown | Dermatoscopy Guided Resection for Skin Cancer NCT06342297 | Region Örebro County | N/A |
| Active Not Recruiting | A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma NCT05888844 | Incyte Corporation | Phase 2 |
| Completed | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK NCT06036836 | Merck Sharp & Dohme LLC | Phase 2 |
| Recruiting | Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC) NCT05377905 | Falo, Louis, MD | Phase 1 / Phase 2 |
| Active Not Recruiting | Complications and Recurrences After Mohs Micrographic Surgery and Slow Mohs NCT06014619 | Maastricht University Medical Center | — |
| Completed | Interobserver Variability Desmoplasia NCT06020612 | Maastricht University Medical Center | — |
| Withdrawn | Cemiplimab/Peg-Interferon-α in Advanced CSCC NCT05729139 | Baptist Health South Florida | Phase 1 |
| Recruiting | Outcome Research of a European Registry Platform on Real-world Treatment Data of Patients with Advanced NMSC NCT05741073 | EuMelaReg gGmbH | — |
| Active Not Recruiting | FLASH Radiotherapy for Skin Cancer NCT05724875 | Centre Hospitalier Universitaire Vaudois | N/A |
| Active Not Recruiting | Deep sequencIng in Cutaneous Squamous CEll caRciNomas NCT05878288 | Peter MacCallum Cancer Centre, Australia | Phase 2 |
| Recruiting | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer NCT05859074 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Cutaneous Squamous Cell Carcinoma Staging Study NCT05695222 | Queen Mary University of London | — |
| Completed | OCT and Invasion in Cutaneous Skin Lesions NCT06014697 | Maastricht University Medical Center | — |
| Active Not Recruiting | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable a NCT04616248 | University of Southern California | Phase 1 |
| Active Not Recruiting | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas NCT05565417 | Immunitas Therapeutics | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer NCT05574101 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Real World Study on the Use of Cemiplimab in Adult Patients in UK NCT05493826 | Sanofi | — |
| Active Not Recruiting | Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders NCT05286294 | Oslo University Hospital | Phase 2 |
| Active Not Recruiting | Exercise to Boost Response to Checkpoint Blockade Immunotherapy NCT05358938 | H. Lee Moffitt Cancer Center and Research Institute | EARLY_Phase 1 |
| Terminated | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selec NCT05256381 | SOTIO Biotech AG | Phase 2 |
| Unknown | The Efficacy and Safety of HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) NCT05238363 | Shanghai Henlius Biotech | Phase 2 |
| Recruiting | MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors NCT05076760 | Memgen, Inc. | Phase 1 |
| Withdrawn | RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and NCT05220748 | Rakuten Medical, Inc. | Phase 1 |
| Completed | Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region NCT05482880 | Maastricht University Medical Center | — |
| Withdrawn | Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma NCT04985825 | Pega-One S.A.S. | Phase 2 |
| Terminated | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With NCT04916002 | Regeneron Pharmaceuticals | Phase 2 |
| Active Not Recruiting | Needs and Preferences of Patients With Head-neck Cutaneous SCC NCT06046625 | Maastricht University Medical Center | — |
| Recruiting | Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck NCT05108090 | Indiana University | N/A |
| Active Not Recruiting | Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Adv NCT04975152 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Recruiting | A Beta-only IL-2 ImmunoTherapY Study NCT05086692 | Medicenna Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma NCT04710498 | Stanford University | Phase 2 |
| Completed | IFx-Hu2.0 for the Treatment of Patients With Skin Cancer NCT04925713 | TuHURA Biosciences, Inc. | Phase 1 |
| Recruiting | Personalised Immunotherapy Platform NCT06536257 | Melanoma Institute Australia | — |
| Terminated | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid NCT04272034 | Incyte Corporation | Phase 1 |
| Active Not Recruiting | Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma NCT04632433 | Fondazione Melanoma Onlus | Phase 2 |
| Unknown | Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck NCT04664582 | Jewish General Hospital | N/A |
| Terminated | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy NCT04596033 | Genocea Biosciences, Inc. | Phase 1 |
| Completed | Cemiplimab in AlloSCT/SOT Recipients With CSCC NCT04339062 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Terminated | Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Ne NCT04502888 | Shattuck Labs, Inc. | Phase 1 |
| Completed | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid NCT04242199 | Incyte Corporation | Phase 1 |
| Completed | Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Sur NCT04620200 | The Netherlands Cancer Institute | Phase 2 |
| Terminated | Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC NCT04242173 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Terminated | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors NCT04301011 | Turnstone Biologics, Corp. | Phase 1 |
| Recruiting | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven NCT04429542 | Bicara Therapeutics | Phase 1 |
| Completed | Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma NCT04154943 | Regeneron Pharmaceuticals | Phase 2 |
| Completed | Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers NCT04160065 | TuHURA Biosciences, Inc. | Phase 1 |
| Unknown | Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions NCT04389112 | University Hospital, Bordeaux | N/A |
| Withdrawn | Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study NCT04252612 | H. Lee Moffitt Cancer Center and Research Institute | EARLY_Phase 1 |
| Terminated | High-Risk Skin Cancers With Atezolizumab Plus NT-I7 NCT03901573 | NeoImmuneTech | Phase 1 / Phase 2 |
| Active Not Recruiting | Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer NCT04050436 | Replimune, Inc. | Phase 2 |
| Unknown | A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessibl NCT03982212 | University of Kansas Medical Center | Phase 1 |
| Completed | CemiplimAb Survivorship Epidemiology NCT03836105 | Regeneron Pharmaceuticals | — |
| Active Not Recruiting | Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cut NCT03969004 | Regeneron Pharmaceuticals | Phase 3 |
| Completed | Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma NCT03889912 | Regeneron Pharmaceuticals | Phase 1 |
| Unknown | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metas NCT03775525 | Genzada Pharmaceuticals USA, Inc. | Phase 1 |
| Completed | Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous NCT03524326 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Active Not Recruiting | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers NCT03212404 | Checkpoint Therapeutics, Inc. | Phase 1 |
| Completed | Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinom NCT03082534 | University of California, San Diego | Phase 2 |
| Completed | New Strategies Against Cutaneous Squamous Cell Carcinoma NCT02672254 | Corporacion Parc Tauli | — |
| Terminated | Treatment With Nab-paclitaxel in Cutaneous SCC NCT02076243 | Icahn School of Medicine at Mount Sinai | Phase 2 |
| Completed | Microarray Analysis of microRNA Expression Profiles in Cutaneous Squamous Cell Carcinoma NCT01500954 | Ruhr University of Bochum | — |
| No Longer Available | Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma NCT03492489 | Regeneron Pharmaceuticals | — |
| Available | IFx-Hu2.0 Expanded Access Program NCT04853602 | TuHURA Biosciences, Inc. | — |